Literature DB >> 28600618

Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.

Xi Xie1, Fen Li2, Shu Li1, Jing Tian1, Jin-Wei Chen1, Jin-Feng Du1, Ni Mao1, Jian Chen1.   

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by progressive joint erosion. Tumor necrosis factor (TNF) antagonists are the most widely used biological disease-modifying anti-rheumatic drug in RA. However, there continue to be one third of RA patients who have poor or no response to TNF antagonists. Following consideration of the uncertainty of therapeutic effects and the high price of TNF antagonists, it is worthy to predict the treatment responses before anti-TNF therapy. According to the comparisons between the responders and non-responders to TNF antagonists by omic technologies, such as genomics, transcriptomics, proteomics, and metabolomics, rheumatologists are eager to find significant biomarkers to predict the effect of TNF antagonists in order to optimize the personalized treatment in RA.

Entities:  

Keywords:  Anti-TNF therapy; Genomics; Metabolomics; Proteomics; Rheumatoid arthritis; Transcriptomics

Mesh：

Substances：

Year:  2017        PMID： 28600618     DOI： 10.1007/s10067-017-3639-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  77 in total

1.  Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.

Authors:  A Chatzikyriakidou; I Georgiou; P V Voulgari; A I Venetsanopoulou; A A Drosos
Journal:  Rheumatology (Oxford)       Date:  2007-04-04       Impact factor: 7.580

2.  Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.

Authors:  Catherine Potter; Heather J Cordell; Anne Barton; Ann K Daly; Kimme L Hyrich; Derek A Mann; Ann W Morgan; Anthony G Wilson; John D Isaacs
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

3.  Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.

Authors:  Helen L Wright; Huw B Thomas; Robert J Moots; Steven W Edwards
Journal:  Rheumatology (Oxford)       Date:  2014-08-13       Impact factor: 7.580

4.  Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis.

Authors:  Y Tanaka; I Matsumoto; K Iwanami; A Inoue; N Umeda; Y Tanaka; M Sugihara; T Hayashi; S Ito; T Sumida
Journal:  Clin Exp Rheumatol       Date:  2012-03-06       Impact factor: 4.473

5.  The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.

Authors:  C P Kang; K W Lee; D H Yoo; C Kang; S C Bae
Journal:  Rheumatology (Oxford)       Date:  2005-02-03       Impact factor: 7.580

Review 6.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

7.  Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

Authors:  Theresa Wampler Muskardin; Priyanka Vashisht; Jessica M Dorschner; Mark A Jensen; Beverly S Chrabot; Marlena Kern; Jeffrey R Curtis; Maria I Danila; Stacey S Cofield; Nancy Shadick; Peter A Nigrovic; E William St Clair; Clifton O Bingham; Richard Furie; William Robinson; Mark Genovese; Christopher C Striebich; James R O'Dell; Geoffrey M Thiele; Larry W Moreland; Marc Levesque; S Louis Bridges; Peter K Gregersen; Timothy B Niewold
Journal:  Ann Rheum Dis       Date:  2015-11-06       Impact factor: 19.103

8.  Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.

Authors:  Sudha Visvanathan; Mahboob U Rahman; Edward Keystone; Mark Genovese; Lars Klareskog; Elizabeth Hsia; Michael Mack; Jacqui Buchanan; Michael Elashoff; Carrie Wagner
Journal:  Arthritis Res Ther       Date:  2010-11-17       Impact factor: 5.156

Review 9.  Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance.

Authors:  Felix Schmidt; Thomas Efferth
Journal:  Pharmaceuticals (Basel)       Date:  2016-06-16

10.  ¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis.

Authors:  Roberta Priori; Luca Casadei; Mariacristina Valerio; Rossana Scrivo; Guido Valesini; Cesare Manetti
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240
View more
  6 in total

1.  Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.

Authors:  Takeshi Iwasaki; Ryu Watanabe; Hiromu Ito; Takayuki Fujii; Kenji Okuma; Takuma Oku; Yoshitaka Hirayama; Koichiro Ohmura; Koichi Murata; Kosaku Murakami; Hiroyuki Yoshitomi; Masao Tanaka; Shuichi Matsuda; Fumihiko Matsuda; Akio Morinobu; Motomu Hashimoto
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

2.  ATRPred: A machine learning based tool for clinical decision making of anti-TNF treatment in rheumatoid arthritis patients.

Authors:  Bodhayan Prasad; Cathy McGeough; Amanda Eakin; Tan Ahmed; Dawn Small; Philip Gardiner; Adrian Pendleton; Gary Wright; Anthony J Bjourson; David S Gibson; Priyank Shukla
Journal:  PLoS Comput Biol       Date:  2022-07-05       Impact factor: 4.779

3.  Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Ioannis Parodis; Marta Novella-Navarro; Ana Martínez-Feito; Victoria Navarro-Compán; Mariana Díaz-Almirón; Dora Pascual-Salcedo; Alejandro Balsa; Chamaida Plasencia-Rodríguez
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

4.  Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Chamaida Plasencia-Rodríguez; Victoria Navarro-Compán; Carlota García-Hoz; Israel Nieto-Gañán; Cristina Sobrino; Javier Bachiller-Corral; Mariana Díaz-Almirón; Ana Martínez-Feito; Teresa Jurado; Paloma Lapuente-Suanzes; Gema Bonilla; Cristina Pijoán-Moratalla; Garbiñe Roy; Mónica Vázquez-Díaz; Alejandro Balsa; Luisa M Villar; Dora Pascual-Salcedo; Eulalia Rodríguez-Martín
Journal:  Front Med (Lausanne)       Date:  2021-06-17

5.  iTRAQ and PRM-Based Proteomic Analysis Provides New Insights into Mechanisms of Response to Triple Therapy in Patients with Rheumatoid Arthritis.

Authors:  Jian Chen; Shu Li; Yan Ge; Jin Kang; Jia-Fen Liao; Jin-Feng Du; Jing Tian; Xi Xie; Fen Li
Journal:  J Inflamm Res       Date:  2021-12-18

6.  A comprehensive database for integrated analysis of omics data in autoimmune diseases.

Authors:  Marta E Alarcón-Riquelme; Pedro Carmona-Sáez; Jordi Martorell-Marugán; Raúl López-Domínguez; Adrián García-Moreno; Daniel Toro-Domínguez; Juan Antonio Villatoro-García; Guillermo Barturen; Adoración Martín-Gómez; Kevin Troule; Gonzalo Gómez-López; Fátima Al-Shahrour; Víctor González-Rumayor; María Peña-Chilet; Joaquín Dopazo; Julio Sáez-Rodríguez
Journal:  BMC Bioinformatics       Date:  2021-06-24       Impact factor: 3.169
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.